Printer Friendly

Genzyme completes acquisition of Ilex Oncology, enters gene therapy collaboration with AGTC.

Genzyme Corporation, Cambridge, MA, announced it has completed its acquisition of Ilex Oncology, a cancer drug development company. The agreement gives Genzyme ownership of Campath, a humanized monoclonal antibody approved by the US Food and Drug Administration (FDA) to treat patients with C-cell chronic lymphocytic leukemia and clofarabine, a next generation purine neculeoside analog designed to inhibit DNA production necessary for cancer cell growth.

Genzyme notes Schering AG holds exclusive worldwide marketing and distribution rights, plus additional exclusive rights in the Pacific Rim for Campath. As part of the settlement with the Federal Trade Commission (FTC) prior to closing the acquisition the company transferred to Schering exclusive responsibility for the development and commercialization of Cantab in solid organ transplantation and Genzyme will no longer receive a share of US profits from the use of the product in transplantation.

The company says it remains committed to the transplantation market and will continue to support the development of Thymoglobulin and its pipeline of other products and candidates in the transplant field.

In addition, Genzyme announced it has entered into a research collaboration with Applied Genetic Technologies (AGTC), Gainesville, FL, a privately held company, to jointly develop novel therapeutics in gene therapy. The company says it has active preclinical development programs, including lysosomal storage disorders, cardiovascular disease, central nervous system and immune-related disorders which may benefit from AGTC's expertise in delivering genets to patients.

Contact: Web site: www.genzyme.com
COPYRIGHT 2005 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Applied Genetic Technologies
Publication:Transplant News
Article Type:Brief Article
Geographic Code:1USA
Date:Jan 15, 2005
Words:237
Previous Article:Consensus conference on pancreas allocation, islet cell transplantation January 23-24 in Miami Beach.
Next Article:DOR BioPharma reports orBec improves mortality rates in leukemia patients following bone marrow transplant.
Topics:


Related Articles
ILEX Oncology and Millennium submit biologics license application for CAMPATH.
Genzyme receives broad patent covering gene therapy for Fabry disease.
Transkaryotic files complaint seeking declaratory judgment against Genzyme.
Transkaryotic announces victory in Genzyme patent litigation.
BioStratum signs kidney disease treatment agreements with Genzyme.
Genzyme Molecular Oncology receives breast and ovarian cancer patent.
Genzyme Biosurgery, Excigen collaborate in developing gene therapy for cardiac arrhythmia.
Genzyme Genetics licenses colon cancer diagnostic.
Genzyme updates timeframe for acquisition of ILEX Oncology; completes Phase 4 Fabrazyme study.
Genzyme signs licensing agreement with UCLA cancer center to develop CML markers.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters